0
0
0
0
1
2
3
$0
Is Regeneron solid or fragile? The Finex Financial Health Scanner reads REGN's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $14.3B |
|---|---|
| Net income | $4.5B |
| Operating margin | 24.9% |
| Net margin | 31.4% |
| Cash and investments | $8.6B |
| Total debt | $2.7B |
| Free cash flow | $2.6B |
| Revenue growth (1 year) | 1.0% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.